... It works differently from other biologics approved to treat HS, like secukinumab (Cosentyx), which targets only IL-17A, and adalimumab (Humira), which is a TNF inhibitor.There is no one-size-fits-all treatment for HS, and the effectiveness of any treatment depends on many factors. ...
Newly Approved Drug Reduces HS Symptoms by 50% in Trials
... It works differently from other biologics approved to treat HS, like secukinumab (Cosentyx), which targets only IL-17A, and adalimumab (Humira), which is a TNF inhibitor.There is no one-size-fits-all treatment for HS, and the effectiveness of any treatment depends on many factors. ...
... Hidradenitis Suppurativa: A Disease of Follicular Epithelium, Rather Than Apocrine Glands — British Journal of Dermatology Hidradenitis Suppurativa: Viewpoint on Clinical Phenotyping, Pathogenesis and Novel Treatments — Experimental Dermatology First Drug for Hidradenitis Suppurativa Approved — MPR New Hope for Hidradenitis Suppurativa: FDA Approves Cosentyx ...
What Is Hidradenitis Suppurativa?
... Hidradenitis Suppurativa: A Disease of Follicular Epithelium, Rather Than Apocrine Glands — British Journal of Dermatology Hidradenitis Suppurativa: Viewpoint on Clinical Phenotyping, Pathogenesis and Novel Treatments — Experimental Dermatology First Drug for Hidradenitis Suppurativa Approved — MPR New Hope for Hidradenitis Suppurativa: FDA Approves Cosentyx ...
... Sold as Cosentyx, secukinumab is given by injection, usually every four weeks after an initial series of doses.In two large clinical trials, people with HS who took secukinumab had fewer painful boils and inflammatory nodules over 16 weeks compared to those who got a placebo. ...
New HS Treatments: Latest FDA-Approved Options
... Sold as Cosentyx, secukinumab is given by injection, usually every four weeks after an initial series of doses.In two large clinical trials, people with HS who took secukinumab had fewer painful boils and inflammatory nodules over 16 weeks compared to those who got a placebo. ...
... These are: Adalimumab (Humira) Bimekizumab-bkzx (Bimzelx) Secukinumab (Cosentyx) What Are the Biosimilars for HS?As of August 2025, all biosimilars for HS are versions of adalimumab, with none currently approved for secukinumab or bimekizumab-bkzx. ...
Alternatives to Biologics: What Are Your Biosimilar Options?
... These are: Adalimumab (Humira) Bimekizumab-bkzx (Bimzelx) Secukinumab (Cosentyx) What Are the Biosimilars for HS?As of August 2025, all biosimilars for HS are versions of adalimumab, with none currently approved for secukinumab or bimekizumab-bkzx. ...
... They are: Adalimumab (Humira) — Blocks tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammation Secukinumab (Cosentyx) — Blocks interleukin (IL)-17A, a chemical messenger involved in inflammation in many chronic diseases Bimekizumab-bkzx (Bimzelx) — The newest FDA-approved biologic for HS, which targets both interleukin (IL)-17A and ...
Biologics for Hidradenitis Suppurativa: How They Work and More
... They are: Adalimumab (Humira) — Blocks tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammation Secukinumab (Cosentyx) — Blocks interleukin (IL)-17A, a chemical messenger involved in inflammation in many chronic diseases Bimekizumab-bkzx (Bimzelx) — The newest FDA-approved biologic for HS, which targets both interleukin (IL)-17A and ...
... Meta-Analysis — Dermatology Rheumatoid Arthritis — Centers for Disease Control and Prevention Rheumatoid Arthritis — American College of Rheumatology Hidradenitis Suppurativa and Rheumatoid Arthritis: Evaluating the Bidirectional Association — Immunologic Research Highlights of Prescribing Information: Humira — RxAbbVie Highlights of Prescribing Information: Cosentyx ...
HS and Rheumatoid Arthritis: What’s the Connection?
... Meta-Analysis — Dermatology Rheumatoid Arthritis — Centers for Disease Control and Prevention Rheumatoid Arthritis — American College of Rheumatology Hidradenitis Suppurativa and Rheumatoid Arthritis: Evaluating the Bidirectional Association — Immunologic Research Highlights of Prescribing Information: Humira — RxAbbVie Highlights of Prescribing Information: Cosentyx ...
... Secukinumab (Cosentyx) — Approved in 2023, secukinumab targets IL-17A, a protein linked to skin inflammation. Bimekizumab-bkzx (Bimzelx) — Approved in 2024, this biologic blocks both IL-17A and IL-17F, offering a two-pronged approach to reducing inflammation. Some doctors may prescribe other biologics off-label for HS. ...
Stopping Biologics Before Surgery: What To Know if You Have HS
... Secukinumab (Cosentyx) — Approved in 2023, secukinumab targets IL-17A, a protein linked to skin inflammation. Bimekizumab-bkzx (Bimzelx) — Approved in 2024, this biologic blocks both IL-17A and IL-17F, offering a two-pronged approach to reducing inflammation. Some doctors may prescribe other biologics off-label for HS. ...
... Food and Drug Administration (FDA) has approved three biologics for treating HS: Adalimumab (Humira) and its biosimilars Bimekizumab (Bimzelx) Secukinumab (Cosentyx) Biologics are given as subcutaneous (under the skin) injections, which you can usually do at home.Some myHSteam members have found relief with biologics. ...
Antibiotics for HS: What You Need To Know
... Food and Drug Administration (FDA) has approved three biologics for treating HS: Adalimumab (Humira) and its biosimilars Bimekizumab (Bimzelx) Secukinumab (Cosentyx) Biologics are given as subcutaneous (under the skin) injections, which you can usually do at home.Some myHSteam members have found relief with biologics. ...
... Food and Drug Administration (FDA) for HS — adalimumab (Humira) and secukinumab (Cosentyx), and bimekizumab (Bimzelx). Infliximab (Remicade) is a biologic drug that is sometimes prescribed off-label for HS. ...
Biologics and Pregnancy: 5 Facts
... Food and Drug Administration (FDA) for HS — adalimumab (Humira) and secukinumab (Cosentyx), and bimekizumab (Bimzelx). Infliximab (Remicade) is a biologic drug that is sometimes prescribed off-label for HS. ...
... Biologics can also decrease HS symptoms like discharge, inflammation, and swelling.Adalimumab (Humira), secukinumab (Cosentyx), and bimekizumab-bkzx (Bimzelx) are biologics approved by the U.S. Food and Drug Administration (FDA) to treat HS. ...
Join
Your Privacy Choices
